Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
- Sotgiu, G
- Lange, C
- Richardson, Md
- Matteelli, A
- Centis, R
- Eker, B
- Guenther, G
- Spanevello, Antonio
- Migliori, Gb
DOIAbstract
We read with interest the study by Koh et al., which continues the discussion on the safety and efficacy of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). The topic is very important as clinicians seek to optimize the few available choices in treating MDR- and XDR-TB patients
Add to ORKG